Sharemaestro Newsreel

Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

Quick Read LTGO priced its IPO at $18, opened at $21, and raised nearly $350 million from an oversubscribed offering. LTG-001 delivered 50% greater pain relief than hydrocodone in a 343-patient trial, positioning it for a first-ever opioid-free label claim. Phase 3 trials launching …

Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before …

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these …

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business …

Here’s What Hurt Boston Scientific Corporation (BSX) in Q2

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve …

AimwellBio Publishes Investor Briefing on Acquired Trustr Intellectual Property Portfolio Valued at $10m Reinforcing Commitment to Transparency

Behavioral engagement technology carries documented institutional lineage spanning Oxford, the University of Vermont, Cornell, AMCP, and a Sanofi pilot program, as inventor Dr. Chris A. Jones joins AimwellBio's Board of Advisors and leads further expansion. MIAMI, FL / ACCESS Newswire / August 13, 2026 …

Priori Expands Client Advisory Board with New Members from Fortune 500 Corporate Legal Departments

Priori Legal operations and legal department leaders from Mastercard, Meta, Google, Uber, General Motors, U.S. Bank, Capital One and more will help shape the future of outside counsel management NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Priori, the legal technology company modernizing outside …

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Omnicell, Inc. OMCL raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund. The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive …

Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation

Edwards Lifesciences Corporation EW shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies. The …

What's Backing Abbott's Established Pharmaceuticals Division Growth

Abbott Laboratories' ABT Established Pharmaceuticals Division ("EPD") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis …

FitLife Brands Inc. (FTLF) Beats Q2 Earnings and Revenue Estimates

FitLife Brands Inc. (FTLF) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …

Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle

Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter …

BD (BDX) Q3 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations - Shawn Bevec Chairman, Chief Executive Officer and President - Tom Polen Executive Vice President and Chief Financial Officer - Vitor Roque Full …

Pfizer CEO Buys $1 Million of Stock

This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials) The pharmaceutical giant earned a new vote of confidence from its top executive. Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership …

Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. …

Zoetis (ZTS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …

This Healthcare Services Stock Has 37% Upside

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, …

Big Tech Drives Up Credit Risk for Safe Firms With No AI Links

(Bloomberg) -- As a flood of debt sales by US tech companies ripples through the credit market, it seems to be triggering an inadvertent rise in risk metrics for some of the world's safest firms. Most Read from Bloomberg Walter Sells Lakers, Seeks More …

Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?

Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets …

Why Gilead Sciences (GILD) Is Back In The Spotlight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate …

NPI's Mitch Gould to Meet With Select Brands at Newtopia Now

Nutritional Products International founder brings decades of retail experience to Denver in search of brands ready to expand in the U.S. market. BOCA RATON, FL / ACCESS Newswire / August 13, 2026 / Nutritional Products International (NPI) founder and CEO Mitch Gould will attend …

5 Insightful Analyst Questions From Henry Schein’s Q2 Earnings Call

5 Insightful Analyst Questions From Henry Schein's Q2 Earnings Call Henry Schein delivered a positive second quarter, with results exceeding Wall Street's expectations and earning a strong market response. Management attributed the outperformance to accelerating internal sales growth, robust gains in its global dental …

US Stock Market Today: S&P 500 Futures Edge Up As Traders Eye Key CPI

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The Morning Bull - US Market Morning Update Thursday, Aug, 13 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P …

Ottobock hebt Prognose für 2026 an – Aktie legt nach starken Quartalszahlen um 3 % zu

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration …

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with …

Jim Cramer’s Surprise AI Pick: Aramark (ARMK)

Jim Cramer has spent months tracking the expanding ripple effects of the artificial intelligence infrastructure boom. He has repeatedly pointed out how secondary beneficiaries are emerging in unexpected places. The theme took center stage when he highlighted Aramark (NYSE:ARMK) after the food services and …

Revisiting Former Stock Picks Medtronic, Quantas Services, Lennar

Reassessing stock picks is one of the best habits an investor can build. Watch Doug discuss recent stock picks, provide input on the current market environment—and take your questions. The daily chart illustrates how well the stock has performed relative to its peers on …

5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management …

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions …

Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected …

5 Insightful Analyst Questions From Merck’s Q2 Earnings Call

5 Insightful Analyst Questions From Merck's Q2 Earnings Call Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic …

Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance …

Demant AS (WILLF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth Fueled by Oticon Zeal ...

This article first appeared on GuruFocus. Revenue Growth: Group reported growth of 15% in H1 2026, with 7% organic growth and 10% acquisitive growth, primarily from KIND. Gross Margin: Increased by 1.1 percentage points, driven by strong ASP in hearing aids and the acquisition …

LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record …

Veeva Systems (VEEV) Exceeds Market Returns: Some Facts to Consider

Veeva Systems (VEEV) closed at $241.51 in the latest trading session, marking a +2.08% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.26% for the day. On the other hand, the Dow registered a loss of …